๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

PCN167 REVIEW OF THE DECISIONS OF HEALTH TECHNOLOGY ASSESSMENT AGENCIES FOR CAPECITABINE FOR THE TREATMENT OF COLORECTAL CANCER

โœ Scribed by MG Saggia; LG Borges


Book ID
118612009
Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
80 KB
Volume
12
Category
Article
ISSN
1098-3015

No coin nor oath required. For personal study only.


๐Ÿ“œ SIMILAR VOLUMES


Capecitabine, a new oral fluoropyrimidin
โœ Francesco Di Costanzo; Andrea Sdrobolini; Silvia Gasperoni ๐Ÿ“‚ Article ๐Ÿ“… 2000 ๐Ÿ› Elsevier Science ๐ŸŒ English โš– 200 KB

Capecitabine (Xeloda) ยฎ was developed as a tumour-selective fluoropyrimidine carbamate to achieve higher intratumoural 5-FU level and lower toxicity than 5-FU. Capecitabine passes unchanged through the gastrointestinal tract and is metabolised in the liver to 5%-deoxy-5-fluorocytidine (5%-DFCR). Her